Gingerol derivative having inhibitory activity against biofilm formation and pharmaceutical composition comprising same as effective ingredient for preventing or treating biofilm-caused infection symptom

Patent metadata

Field	Value
Publication number	US-11964935-B2
Application number	US-201816632592-A
Country	US
Kind code	B2
Filing date	Jul 19, 2018
Priority date	Jul 20, 2017
Publication date	Apr 23, 2024
Grant date	Apr 23, 2024

Abstract

The present invention relates to a gingerol derivative having inhibitory activity against biofilm formation and a pharmaceutical composition for preventing or treating infections caused by biofilms including the gingerol derivative as an active ingredient. The gingerol derivative of the present invention exhibits significantly improved binding affinity for LasR and inhibitory activity against biofilm formation. Therefore, the gingerol derivative of the present invention can act on various membrane surfaces where biofilms tend to form and can effectively inhibit the formation of the corresponding biofilms. In addition, the use of the pharmaceutical composition according to the present invention can fundamentally prevent or treat a variety of infections caused by biofilms due to the presence of the gingerol derivative in the pharmaceutical composition.

First claim

The invention claimed is:

1. A gingerol derivative represented by Formula 13 to 17, 20 to 22, 25, and 26:

2. The gingerol derivative according to claim 1 , wherein the gingerol derivative inhibits biofilm formation.

3. The gingerol derivative according to claim 2 , wherein the biofilm is formed by one or more bacterial species selected from the group consisting of Pseudomonas aeruginosa, Salmonella spp., Shigella spp., Vibrio parahaemolyticus, Vibrio choreae, Escherichia coli O-157, Campylobacter jejuni, Clostridium difficile, Clostridium perfringens, Yersinia enterocolitica, Helicobacter pylori, Entemoeba histolytica, Bacillusu cereus, Clostridium botulinum, Haemophilus influenzae, Streptococcus pneumoniae, Chlamidia pneumoniae, Legionella pneumoniae, Branhamella catarrhalis, Mycobacterium tuberculosis, Mycoplasma pneumoniae, Storeptcoccus pyogenes, Corynebacterium diphtheriae, Bordetella pertussis, Chramidia psittaci, methicillin resistant Staphylococcus aureus (MRSA), Escherichia coli, Klebsiella pneumoniae, Enterobacter spp., Proteus spp., Acinetobacter spp., Enterococcus faecalis, Staphylococcus saprophyticus , and Storeptcoccus agalactiae.

4. A composition for inhibiting biofilm formation comprising the gingerol derivative according to claim 1 .

5. A pharmaceutical composition for preventing or treating infections caused by biofilms comprising the gingerol derivative according to claim 1 or a pharmaceutically acceptable salt thereof as an active ingredient.

6. The pharmaceutical composition according to claim 5 , wherein the infections are selected from the group consisting of cystic fibrosis, pneumonia, dental caries, periodontitis, otitis media, musculoskeletal infections, necrotizing fasciitis, biliary tract infection, osteomyelitis, bacterial prostatitis, native valve endocarditis, melioidosis, nosocomial infection, ICU pneumonia, urinary catheter cystitis, peritoneal dialysis (CAPD) peritonitis, and biliary stent blockage.

Assignees

• Univ Korea Res & Business Foundation Sejong Campus
• Univ Korea Res & Bus Found

Inventors

• BYUN Youngjoo
• Park Hee-Deung
• Son Sang-Hyun
• Cha Eunji
• Ham So-Young
• Choi Hyunsuk

Classifications

• C07C49/255 Primary

  containing ether groups, [IMAGE cpc-sch-C07C-0958.gif] groups,[IMAGE cpc-sch-C07C-0959.gif] groups, or[IMAGE cpc-sch-C07C-0960.gif] groups · CPC title

• A61P31/04 Primary

  Antibacterial agents · CPC title

• C07C49/245

  containing six-membered aromatic rings · CPC title

• A61K31/12 Primary

  Ketones · CPC title

• Y02A50/30

  Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change · CPC title